Jaguar Health Inc (NASDAQ: JAGX) has had an incredible run in the market as of late, and that is continuing in today’s trading session. The gains come for good reason. The company recently announced news that it received information from the FDA, bringing the company’s lead veterinary clinical candidate closer to commercialization. Today, we’ll talk about the news, what we’re seeing from JAGX, and what we’ll be watching for ahead.
JAGX Continues To Fly On FDA News
As mentioned above, Jaguar Health is having yet another incredible day in the market as the stock continues to run on FDA news. In a press release issued on Thursday of last week, the company announced that the FDA indicated that the company’s reasonable expectation of effectiveness technical section is complete for use of Canalevia for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
In the release, the company explained that Canalevia, it’s lead veterinary drug product candidate, is a canine-specific oral formulation of crofelemer. Crofelemer is an active pharmaceutical ingredient. In a statement, Dr. Michael Guy, DVM, MS, Ph.D., Vice President and Clinical Veterinarian at JAGX, had the following to offer:
Jaguar has now completed two of the four required technical sections of the Company’s application for conditional approval of Canalevia for CID in dogs. With receipt of conditional approval for this indication, we would expect to conduct the commercial launch for Canalevia for CID in dogs in mid-2019.
What We’re Seeing From The Stock
As investors, one of the first lessons that we learn is that the news moves the market. Ultimately, the news released by Jaguar proved to be overwhelmingly positive. After all, this news brings Canalevia one step closer to commercialization, something that the company believes is only about a year away. So, we’ve seen some strong gains in recent sessions, as a result of the news, that are continuing today. Currently (10:08), JAGX is trading at $0.24 per share after a gain of $0.02 per share (6.77%) thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on JAGX. In particular, we’re interested in following the continued work surrounding Canalevia as well as the rest of the company’s pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!